Study guide

12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)

Philippine Medical Technologists Licensure Examination MTLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety

1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards

2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function

2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice

3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology

3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology

4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety

4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms

5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria

5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology

6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology

6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods

7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods

7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control

8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders

8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry

9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders

9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests

10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing

10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures

11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions

11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin

12 Chapter 12: Clinical Serology and Immunology

12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)

13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology

13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control

14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens

14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens

15 Chapter 15: Histopathologic Techniques and Cytotechnology

15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records

16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics

16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics

12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)

Key Takeaways Explain This Topic AI

Antinuclear antibody (ANA) indirect immunofluorescence on HEp-2 cells reveals distinct morphologic nuclear patterns: rim/peripheral is highly specific for dsDNA and active lupus nephritis, homogeneous targets dsDNA/histones in SLE and drug-induced lupus, and speckled targets extractable nuclear antigens (anti-Sm, anti-RNP, anti-SSA/Ro, anti-SSB/La).

Anti-cyclic citrullinated peptide (anti-CCP) antibodies provide >95% diagnostic specificity for rheumatoid arthritis, far surpassing rheumatoid factor (RF, IgM anti-human IgG Fc) which is frequently elevated in chronic hepatitis, subacute bacterial endocarditis, and normal aging.

The Coombs and Gell classification stratifies hypersensitivity into four mechanistic types: Type I (IgE-mediated immediate), Type II (antibody-dependent cytotoxic), Type III (soluble immune-complex deposition), and Type IV (delayed-type cell-mediated).

Human Leukocyte Antigen (HLA) class I molecules (HLA-A, -B, -C) present endogenous intracellular peptides to CD8+ cytotoxic T cells, while class II molecules (HLA-DP, -DQ, -DR) present exogenous peptides to CD4+ helper T cells, exhibiting profound disease correlations such as HLA-B27 in ankylosing spondylitis.

Primary immunodeficiency disorders stem from distinct genetic arrests: X-linked Bruton agammaglobulinemia displays absent circulating B cells and profound hypogammaglobulinemia, SCID cripples both cellular and humoral branches, and DiGeorge syndrome manifests thymic hypoplasia with impaired T-cell maturation and hypocalcemia.

Last updated: October 2026

Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)

Autoimmune disorders, hypersensitivity reactions, histocompatibility testing, and primary immunodeficiency syndromes represent the highest level of clinical complexity in medical laboratory immunology. Autoimmunity arises when breakdown of central or peripheral tolerance allows autoreactive lymphocytes and autoantibodies to target self-antigens. For the medical technologist, mastering antinuclear antibody (ANA) immunofluorescence patterns on human epithelial HEp-2 cells, deciphering rheumatoid arthritis and ANCA biomarkers, classifying immunopathologic hypersensitivity mechanisms, understanding Human Leukocyte Antigen (HLA) genetics, and recognizing primary immunodeficiencies are vital for passing the Philippine Medical Technologists Licensure Examination (MTLE) and performing accurate diagnostic testing.

1. Antinuclear Antibody (ANA) Testing and Autoimmune Diagnostic Profiles

Antinuclear antibodies (ANAs) are autoantibodies directed against various nuclear, nucleolar, and cytoplasmic components of human cells. Testing for ANAs is the standard initial laboratory evaluation in patients suspected of having systemic autoimmune rheumatic diseases (SARD), particularly Systemic Lupus Erythematosus (SLE) .

Indirect Immunofluorescence (IIF) on HEp-2 Cells

Gold Standard Substrate : Indirect immunofluorescence utilizing HEp-2 cells (human epithelial cells derived from laryngeal carcinoma) is the international reference standard. HEp-2 cells offer large, prominent nuclei and a high mitotic index ( 3 – 5 % 3\text{--}5\% 3 – 5% of cells actively dividing), facilitating visualization of cell-cycle-dependent antigens (e.g., centromere and PCNA).

Screening Dilution : Patient serum is routinely screened at an initial dilution of 1 : 40 to 1 : 160 1:40\text{ to }1:160 1 : 40 to 1 : 160 (commonly 1 : 80 1:80 1 : 80 or 1 : 160 1:160 1 : 160 ). Titers ≥ 1 : 160 \ge 1:160 ≥ 1 : 160 are considered clinically significant; titers of 1 : 40 1:40 1 : 40 to 1 : 80 1:80 1 : 80 occur in 5 % to 15 % 5\%\text{ to }15\% 5% to 15% of healthy individuals, particularly elderly females.

Reading and Grading : Bound autoantibodies are visualized using FITC-conjugated goat anti-human IgG under a fluorescence microscope. Results are reported with both the predominant fluorescent staining pattern and the endpoint titer (e.g., "Speckled pattern, titer 1:640"). ┌────────────────────────────┬─────────────────────────────┬──────────────────────────────┐

  • │ ANA IIF Pattern on HEp-2 │ Target Antigens │ Primary Disease Association │
  • ├────────────────────────────┼─────────────────────────────┼──────────────────────────────┤
  • │ Homogeneous (Diffuse) │ dsDNA, Histones, │ Systemic Lupus Erythematosus,│
  • │ (Mitotics: Chromosomes (+))│ Nucleosomes │ Drug-Induced Lupus (>95% H) │
  • ├────────────────────────────┼─────────────────────────────┼──────────────────────────────┤
  • │ Peripheral (Rim) │ Double-stranded DNA (dsDNA) │ SLE (Correlates with active │
  • │ (Mitotics: Chromosomes (+))│ │ nephritis & hypocomplement) │
  • ├────────────────────────────┼─────────────────────────────┼──────────────────────────────┤
  • │ Speckled │ Extractable Nuclear Ags: │ SLE (anti-Sm pathognomonic), │
  • │ (Mitotics: Chromosomes (-))│ Sm, U1-RNP, SSA/Ro, SSB/La │ MCTD (anti-RNP), Sjögren │
  • ├────────────────────────────┼─────────────────────────────┼──────────────────────────────┤
  • │ Centromere (Discrete) │ Kinetochore / Centromere │ Limited Cutaneous Sclero- │
  • │ (Mitotics: Metaphase line) │ proteins (CENP-A, B, C) │ derma (CREST Syndrome, >80%) │
  • ├────────────────────────────┼─────────────────────────────┼──────────────────────────────┤
  • │ Nucleolar │ RNA polymerase I, │ Diffuse Systemic Sclerosis │
  • │ (Clumped nucleoli only) │ Fibrillarin (U3-snoRNP) │ (Scleroderma) │
  • └────────────────────────────┴─────────────────────────────┴──────────────────────────────┘
  • The Five Classic ANA Patterns and Clinical Correlations

Homogeneous (Diffuse) Pattern :

Microscopic Appearance : Solid, uniform, smooth fluorescence across the entire interphase nucleus. In actively dividing mitotic cells, the condensed chromosomal plates stain intensely.

Antigenic Targets : Native double-stranded DNA ( dsDNA ), core histones (H1, H2A, H2B, H3, H4), and nucleosomes.

Clinical Correlations : Systemic Lupus Erythematosus (SLE); Drug-Induced Lupus (DIL) . In drug-induced lupus (triggered by procainamide, hydralazine, isoniazid, minocycline, or quinidine), anti-histone antibodies are present in > 95 % >95\% > 95% of cases , with absent anti-dsDNA and normal complement levels.

Peripheral (Rim / Shaggy) Pattern :

Microscopic Appearance : Bright, intense fluorescent ring localized along the outer perimeter (nuclear envelope) of the nucleus, with fading fluorescence toward the center. Mitotic chromosomes stain brightly.

Antigenic Targets : Exclusively directed against native dsDNA (and nuclear lamins).

Clinical Correlations : Highly specific for Systemic Lupus Erythematosus (SLE) . The presence and rising titer of anti-dsDNA correlate directly with active lupus nephritis and systemic complement consumption (depressed serum C3 and C4).

Speckled Pattern :

Microscopic Appearance : Fine or coarse grain-like fluorescent speckles distributed throughout the nucleoplasm, sparing the dark nucleoli. In dividing mitotic cells, the metaphase chromosomes are completely dark (negative).

Antigenic Targets : Non-histone proteins known as Extractable Nuclear Antigens (ENA) :

Anti-Sm (Smith) : Directed against core proteins of the U1, U2, U4/U6, and U5 small nuclear ribonucleoprotein (snRNP) particles. Pathognomonic and highly specific for SLE (included in ACR and SLICC classification criteria), though present in only 20 % to 30 % 20\%\text{ to }30\% 20% to 30% of patients.

Anti-U1-RNP : High titers ( > 1 : 1 , 000 >1:1,000 > 1 : 1 , 000 ) are the diagnostic sine qua non for Mixed Connective Tissue Disease (MCTD) (present in 95 % to 100 % 95\%\text{ to }100\% 95% to 100% of cases; presents with overlapping features of SLE, systemic sclerosis, and polymyositis).

Anti-SSA (Ro) and Anti-SSB (La) : Strongly associated with Sjögren syndrome (anti-SSA in 70 % 70\% 70% , anti-SSB in 50 % 50\% 50% ) and subacute cutaneous lupus. Maternal anti-SSA antibodies cross the placenta and can cause Neonatal Lupus Erythematosus complicated by congenital complete heart block (third-degree atrioventricular block).

Anti-Scl-70 (DNA Topoisomerase I) : High specificity for diffuse systemic sclerosis (scleroderma) with extensive cutaneous involvement and pulmonary interstitial fibrosis.

Centromere Pattern (Discrete Speckled) :

Microscopic Appearance : 40 to 60 discrete, uniform, bright speckles scattered throughout the interphase nucleoplasm. During cell division (mitosis), these speckles concentrate and align in a crisp, sharp line along the equatorial metaphase plate .

Antigenic Targets : Centromeric kinetochore proteins ( CENP-A, CENP-B, CENP-C ).

Clinical Correlations : Pathognomonic for limited cutaneous systemic sclerosis / CREST syndrome (Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasia), occurring in 70 % to 90 % 70\%\text{ to }90\% 70% to 90% of patients.

Nucleolar Pattern :

Microscopic Appearance : Intense, selective fluorescence of the nucleoli (1 to 6 clumps per nucleus) with unstained nucleoplasm and dark mitotic chromosomes.

Antigenic Targets : RNA polymerase I, fibrillarin (U3-snoRNP), and PM-Scl.

Clinical Correlations : Systemic sclerosis (scleroderma) and polymyositis-scleroderma overlap syndromes.

  • 2. Rheumatoid Arthritis Serology and ANCA Vasculitis Markers
  • Rheumatoid Arthritis (RA) Serological Biomarkers

Rheumatoid arthritis is a chronic, systemic inflammatory autoimmune disorder characterized by symmetric, destructive polyarthritis targeting diarthrodial joints:

Rheumatoid Factor (RF) :

Definition: Autoantibodies directed against the Fc portion of human IgG . Classically measured as IgM anti-IgG via latex agglutination or nephelometry.

Diagnostic Utility: Positive in 70 % to 80 % 70\%\text{ to }80\% 70% to 80% of patients with established RA. However, RF has poor diagnostic specificity . It is frequently elevated in other conditions: chronic Hepatitis C, Subacute Bacterial Endocarditis (SBE), tuberculosis, leprosy, syphilis, sarcoidosis, Sjögren syndrome, and in 5 % to 10 % 5\%\text{ to }10\% 5% to 10% of healthy elderly individuals.

Anti-Cyclic Citrullinated Peptide (Anti-CCP / ACPA) :

Definition: Antibodies directed against synthetic cyclic peptides containing the non-standard amino acid citrulline , formed by the enzymatic post-translational modification of arginine residues by peptidylarginine deiminase (PADI) in inflamed synovium.

Diagnostic Superiority: Anti-CCP exhibits comparable sensitivity to RF ( 70 % to 80 % 70\%\text{ to }80\% 70% to 80% ) but extraordinary specificity ( > 95 % to 98 % >95\%\text{ to }98\% > 95% to 98% ) for rheumatoid arthritis. Anti-CCP antibodies are detectable 5 to 10 years before the onset of clinical arthritis and strongly predict aggressive, erosive joint damage.

Anti-Neutrophil Cytoplasmic Antibodies (ANCA)

ANCAs are autoantibodies directed against primary azurophilic granule enzymes of human neutrophils, visualized via indirect immunofluorescence on ethanol-fixed buffy coat neutrophils:

Cytoplasmic ANCA (c-ANCA) :

Microscopic Pattern: Diffuse, coarse granular fluorescence throughout the cytoplasm with prominent interlobular accentuation between nuclear lobes.

Antigenic Target: Proteinase-3 (PR3) , a neutral serine protease.

Clinical Correlation: Highly sensitive ( > 90 % >90\% > 90% ) and specific for Granulomatosis with Polyangiitis (GPA, formerly Wegener's granulomatosis) . Antibody titers correlate closely with clinical disease activity and disease relapse.

Perinuclear ANCA (p-ANCA) :

Microscopic Pattern: Intense fluorescence concentrated in a smooth collar around the nuclear membrane lobes. (This pattern is an artifact of ethanol fixation; basic granule proteins migrate toward the acidic cell nucleus).

Antigenic Target: Myeloperoxidase (MPO) .

Clinical Correlation: Associated with Microscopic Polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA / Churg-Strauss syndrome) . Differentiated from co-existing ANA interference by secondary testing on formalin-fixed neutrophils (where MPO remains within the cytoplasm, reverting to a cytoplasmic pattern).

3. Coombs and Gell Classification of Hypersensitivity Reactions

Hypersensitivity refers to exaggerated, inappropriate immune reactions that cause tissue damage, organ dysfunction, or death upon re-exposure to an antigen. The classic Coombs and Gell classification stratifies hypersensitivity into four mechanistic categories (Types I, II, III, and IV): ┌────────────────────────────┬─────────────────────────────┬──────────────────────────────┐

  • │ Hypersensitivity Type │ Primary Immune Mediator │ Classic Clinical Entities │
  • ├────────────────────────────┼─────────────────────────────┼──────────────────────────────┤
  • │ Type I: Immediate / │ IgE antibodies cross-link │ Anaphylaxis (penicillin, bee │
  • │ Anaphylactic │ FcεRI on mast cells and │ venom), allergic asthma, │
  • │ (Minutes to hours) │ basophils ──► Histamine │ allergic rhinitis, urticaria │
  • ├────────────────────────────┼─────────────────────────────┼──────────────────────────────┤
  • │ Type II: Cytotoxic / │ IgG or IgM directed against │ Goodpasture (anti-GBM), AIHA,│
  • │ Antibody-Mediated │ fixed cell/tissue antigens; │ HDFN (anti-Rh), Myasthenia │
  • │ (Hours to days) │ Lysis (C'), ADCC, phagocyte │ Gravis, Graves disease │
  • ├────────────────────────────┼─────────────────────────────┼──────────────────────────────┤
  • │ Type III: Immune Complex- │ Soluble antigen-antibody │ SLE (lupus nephritis), Serum │
  • │ Mediated │ complexes deposit in vessel │ Sickness, Post-Streptococcal │
  • │ (Hours to days) │ walls; Complement & PMNs │ Glomerulonephritis, Arthus │
  • ├────────────────────────────┼─────────────────────────────┼──────────────────────────────┤
  • │ Type IV: Delayed-Type / │ Sensitized T-lymphocytes │ Contact dermatitis (nickel, │
  • │ Cell-Mediated │ (CD4+ Th1/Th17, CD8+ CTL); │ poison ivy), Mantoux PPD │
  • │ (24 to 72 hours) │ Cytokines (IFN-γ) & Mφ │ test, TB granulomas, chronic │
  • │ │ (NO antibodies involved!) │ allograft rejection │
  • └────────────────────────────┴─────────────────────────────┴──────────────────────────────┘
  • Mechanistic Details of Hypersensitivity Types

Type I: Immediate (Anaphylactic) Hypersensitivity :

Sensitization Phase : Allergen triggers Th2 activation, I L - 4 IL\text{-}4 I L - 4 and I L - 13 IL\text{-}13 I L - 13 secretion, driving B-cell class switching to IgE. Secreted IgE binds high-affinity F c ϵ R I Fc\epsilon RI F cϵ R I receptors on mast cells and basophils.

Effector Phase : Re-exposure to multivalent allergen cross-links membrane-bound IgE. Intracellular signaling triggers explosive degranulation, releasing preformed primary mediators (histamine, heparin, tryptase, eosinophil chemotactic factor) and synthesized secondary lipid mediators (leukotrienes L T C 4 , L T D 4 , L T E 4 LTC_4, LTD_4, LTE_4 L T C 4 ​ , L T D 4 ​ , L T E 4 ​ [slow-reacting substance of anaphylaxis, SRS-A] causing profound bronchoconstriction and mucus secretion; prostaglandin P G D 2 PGD_2 PG D 2 ​ ).

Type II: Cytotoxic (Antibody-Mediated) Hypersensitivity :

Mechanism : IgG or IgM antibodies bind directly to fixed, insoluble cell-surface or extracellular matrix antigens . Target destruction occurs via: (a) Classical complement activation causing MAC lysis; (b) Opsonization and phagocytosis by splenic macrophages expressing Fc receptors ( F c γ R I Fc\gamma RI F c γ R I ) and complement receptors ( C R 1 CR1 CR 1 ); or (c) Antibody-Dependent Cellular Cytotoxicity (ADCC) mediated by NK cells.

Non-Cytotoxic Functional Variants : Antibodies stimulate or block receptor signaling without cell destruction (e.g., thyroid-stimulating immunoglobulins [TSI] activating TSH receptors in Graves disease ; blocking anti-acetylcholine receptor [anti-AChR] antibodies in Myasthenia Gravis ).

Type III: Immune Complex-Mediated Hypersensitivity :

Mechanism : Soluble circulating antigen and antibody (IgG/IgM) combine in moderate antigen excess , forming intermediate-sized immune complexes that escape phagocytic clearance by the reticuloendothelial system.

Tissue Deposition : Complexes deposit in blood vessel walls, synovial membranes, and glomerular capillary basement membranes. Deposited complexes fix complement, generating C 3 a C3a C 3 a and C 5 a C5a C 5 a that recruit neutrophils. Neutrophils undergo "frustrated phagocytosis" , releasing lysosomal elastases, collagenases, and oxygen free radicals that cause fibrinoid necrosis and necrotizing vasculitis .

Microscopic Pathology : Renal biopsy demonstrates a distinct granular ("lumpy-bumpy") immunofluorescent deposition along capillary loops, distinguishing Type III from the smooth linear pattern of Type II Goodpasture syndrome.

Type IV: Delayed-Type Hypersensitivity (DTH) / Cell-Mediated :

Distinguishing Hallmark : Completely independent of antibodies and complement . Mediated exclusively by antigen-sensitized T-lymphocytes.

Induction and Elicitation : Memory CD4+ T-helper cells (Th1 and Th17) recognize presented peptide antigens on APCs and secrete pro-inflammatory cytokines: Interferon-gamma (IFN- γ \gamma γ ) , which activates tissue macrophages, and Tumor Necrosis Factor (TNF) . Macrophages produce nitric oxide, lysosomal enzymes, and undergo fusion into multinucleated Langhans giant cells, forming caseating granulomas in chronic tuberculosis.

Time Course : Delayed kinetics; manifestations require 24 to 72 hours to reach maximal induration and erythema (e.g., Mantoux tuberculin purified protein derivative [PPD] skin test read at 48 – 72 hours 48\text{--}72\text{ hours} 48 – 72 hours ; contact dermatitis to urushiol from poison ivy or nickel sulfate).

4. Major Histocompatibility Complex (MHC / HLA) Architecture and Disease Genetics

The Human Leukocyte Antigen (HLA) system is encoded by the Major Histocompatibility Complex (MHC), a gene-dense region on the short arm of chromosome 6 ( 6 p 21.3 6p21.3 6 p 21.3 ) . HLA molecules display peptide fragments on cell surfaces for surveillance by T-lymphocytes. ┌────────────────────────────┬─────────────────────────────┬──────────────────────────────┐

  • │ Characteristic │ Class I MHC (HLA-A, B, C) │ Class II MHC (HLA-DP, DQ, DR)│
  • ├────────────────────────────┼─────────────────────────────┼──────────────────────────────┤
  • │ Molecular Polypeptide │ Polymorphic α heavy chain │ Polymorphic α chain (34 kDa) │
  • │ Architecture │ (44 kDa) + Invariant β2- │ + Polymorphic β chain │
  • │ │ microglobulin (12 kDa, Chr15│ (29 kDa) │
  • ├────────────────────────────┼─────────────────────────────┼──────────────────────────────┤
  • │ Peptide-Binding Cleft │ Closed cleft (α1 and α2 │ Open cleft (α1 and β1 │
  • │ │ domains); Binds 8-10 amino │ domains); Binds 13-25 amino │
  • │ │ acid peptides │ acid peptides │
  • ├────────────────────────────┼─────────────────────────────┼──────────────────────────────┤
  • │ Cellular Distribution │ All nucleated cells and │ Restricted to Professional │
  • │ │ platelets (absent on mature │ APCs: Dendritic cells, │
  • │ │ erythrocytes) │ B-cells, Macrophages │
  • ├────────────────────────────┼─────────────────────────────┼──────────────────────────────┤
  • │ Antigen Presentation │ Endogenous peptides (viral, │ Exogenous peptides (bacteria,│
  • │ Pathway & T-Cell Target │ tumor, self) presented to │ endocytosed antigens) to │
  • │ │ CD8+ Cytotoxic T-cells │ CD4+ Helper T-cells │
  • └────────────────────────────┴─────────────────────────────┴──────────────────────────────┘
  • High-Yield Clinical HLA Disease Associations (MTLE Board Exam Favorites)

Specific HLA alleles confer extraordinary relative risks ( R R RR RR ) for specific autoimmune and autoinflammatory conditions:

HLA-B27 :

Ankylosing Spondylitis (AS) : > 90 % >90\% > 90% of patients carry HLA-B27 (Relative Risk > 80 – 100 >80\text{--}100 > 80 – 100 ).

Other seronegative spondyloarthropathies: Reactive Arthritis (Reiter syndrome) , Psoriatic Arthritis, and Acute Anterior Uveitis.

HLA-DR3 and HLA-DR4 :

Type 1 Diabetes Mellitus (T1DM) : DR3/DR4 heterozygotes possess the highest genetic risk.

HLA-DR3 is also linked to Systemic Lupus Erythematosus and Hashimoto thyroiditis.

HLA-DR4 is strongly associated with Rheumatoid Arthritis (shared epitope hypothesis) and Pemphigus vulgaris.

HLA-DR2 :

Multiple Sclerosis (MS) and Goodpasture syndrome.

HLA-DQ2 and HLA-DQ8 :

Celiac Disease (Gluten-Sensitive Enteropathy) : Present in > 98 % >98\% > 98% of celiac patients; absence has > 99 % >99\% > 99% negative predictive value.

5. Primary Immunodeficiency Syndromes: Genetics and Laboratory Findings

Primary immunodeficiency disorders are inherited genetic defects that impair development, maturation, or function of immune cells:

X-Linked Agammaglobulinemia (XLA / Bruton's Disease) :

Genetic Defect : Inactivating mutation in the BTK gene (Bruton tyrosine kinase) located on chromosome X q 21.3 – q 22 Xq21.3\text{--}q22 Xq 21.3 – q 22 . BTK is a cytoplasmic tyrosine kinase essential for signal transduction from the pre-B cell receptor. Mutation blocks differentiation of pre-B cells into mature B-lymphocytes in the bone marrow.

Laboratory Profile : Profound reduction or complete absence of circulating mature B-cells ( CD19+ and CD20+ B-cells < 1 % <1\% < 1% ; normal is 5 – 15 % 5\text{--}15\% 5 – 15% ). Plasma cells are completely absent from lymphoid tissues. Total serum immunoglobulins are profoundly depressed ( IgG < 100 mg/dL <100\text{ mg/dL} < 100 mg/dL , undetectable IgA, IgM, IgD, and IgE). Cell-mediated immunity is completely intact : normal circulating CD3+ T-cell counts, normal mitogen proliferation, and intact delayed-type hypersensitivity.

Clinical Features : Affected male infants appear healthy during the first 5 to 6 months of life due to protective transplacental maternal IgG. As maternal antibody decays, infants present with recurrent, life-threatening pyogenic sinopulmonary infections caused by encapsulated bacteria ( Streptococcus pneumoniae , Haemophilus influenzae , Moraxella catarrhalis ). Lymph nodes and pharyngeal tonsils are strikingly small or absent.

Severe Combined Immunodeficiency (SCID) :

Genetic Defect : Heterogeneous group of genetic defects crippling both cell-mediated and humoral immunity:

X-Linked SCID ( 50 % 50\% 50% ) : Mutation in the I L 2 R G IL2RG I L 2 RG gene encoding the common gamma chain ( γ c \gamma_c γ c ​ ) shared by receptors for I L - 2 , I L - 4 , I L - 7 , I L - 9 , I L - 15 , IL\text{-}2, IL\text{-}4, IL\text{-}7, IL\text{-}9, IL\text{-}15, I L - 2 , I L - 4 , I L - 7 , I L - 9 , I L - 15 , and I L - 21 IL\text{-}21 I L - 21 . Lack of I L - 7 IL\text{-}7 I L - 7 signaling abolishes T-cell development; lack of I L - 15 IL\text{-}15 I L - 15 halts NK cell development ( T − B + N K − T^- B^+ NK^- T − B + N K − phenotype).

Autosomal Recessive SCID : Due to Adenosine Deaminase (ADA) deficiency ( 15 % to 20 % 15\%\text{ to }20\% 15% to 20% ). Deficiency of ADA leads to toxic intracellular accumulation of deoxyadenosine and deoxy-ATP, which poison DNA synthesis and induce rapid apoptosis of immature T, B, and NK lymphocytes ( T − B − N K − T^- B^- NK^- T − B − N K − phenotype).

Laboratory Profile : Extreme lymphopenia (absolute lymphocyte count < 1 , 500 / μ L <1,500/\mu\text{L} < 1 , 500/ μ L in infants); near-zero circulating T-cells (CD3+); markedly depressed immunoglobulins; complete cutaneous anergy.

Clinical Course : "Bubble boy" disease. Severe opportunistic infections ( Pneumocystis jirovecii , candidiasis, CMV), chronic intractable diarrhea, and failure to thrive within the first few months of life. Fatal within the first year unless reconstituted by hematopoetic stem cell transplantation (HSCT) or gene therapy.

DiGeorge Syndrome (22q11.2 Deletion / Thymic Hypoplasia) :

Genetic Defect : Microdeletion on chromosome 22 q 11.2 22q11.2 22 q 11.2 causing defective embryological development of the third and fourth pharyngeal pouches between weeks 6 and 10 of gestation.

Organ Failures : Failure of pharyngeal pouch differentiation causes congenital absence or hypoplasia of both the thymus gland and parathyroid glands , accompanied by aortic arch anomalies.

Clinical Triad (CATCH-22) : C ardiac defects (Tetralogy of Fallot, truncus arteriosus), A bnormal facies (hypertelorism, micrognathia), T hymic hypoplasia (severe cellular immunodeficiency with deficient CD3+ T-cell maturation), C left palate, and H ypocalcemia (due to absent parathyroid glands and PTH deficiency, presenting as neonatal tetany and seizures within 24 to 48 hours of birth).

Laboratory Profile : Profoundly depressed peripheral CD3+ T-cell counts with defective cell-mediated immunity; serum calcium is critically low ( < 7.0 mg/dL <7.0\text{ mg/dL} < 7.0 mg/dL ), serum parathyroid hormone (PTH) is undetectable, and chest radiography confirms absent thymic shadow.